yttrium-90 + tyrosine kinase inhibitor

This is a combination therapy consisting of yttrium-90 (Y-90) radioembolization and a tyrosine kinase inhibitor (TKI). Yttrium-90 is a radiopharmaceutical used in transarterial radioembolization to deliver targeted radiation to liver tumors. Tyrosine kinase inhibitors are small molecule drugs that block the activity of various kinases involved in tumor growth and angiogenesis. The combination aims to enhance antitumor efficacy by leveraging the local cytotoxic effects of Y-90 with the systemic inhibition of oncogenic signaling pathways by TKIs. This approach has been studied primarily in hepatocellular carcinoma (HCC) and other liver-dominant malignancies, with research focusing on safety, timing, toxicity profiles, and potential synergistic effects[1][2].

Other names

yttrium-90 plus tyrosine kinase inhibitoryttrium90 plus tyrosine kinase inhibitoryttrium 90 plus tyrosine kinase inhibitorY90 + TKI90Y + TKI